Drug discovery and development company Scynexis has made three new senior management appointments, including the chief financial officer from Nobex Corp.
Charles Osborne will leave his post as CFO at Nobex in RTP to assume the same role for Scynexis, which is also based in RTP. Osborne replaces Bruce Lowery, a partner with Tatum Partners who had held the interim chief financial officer role at Scynexis for several years.
At Nobex, Osborne completed two large venture capital rounds totaling more than $60 million, including $35 million in 2002. He also was involved in structuring and negotiating corporate licenses and research agreements with pharmaceutical companies, including with GlaxoSmithKline.
Previously, Osborne was vice president of finance for International Murex Technologies Company, a publicly traded medical diagnostics company. While at Murex, he ran the worldwide finance group while based in London and assisted with the sale of the company to Abbott Laboratories.
In addition to the hire of Osborne, Scynexis has created and filled two new senior management positions. Brian Schwab joins the company as chief licensing officer and general counsel.
Schwab most recently has served as deputy general counsel for Aventis CropScience in Lyon, France, where he managed a team of attorneys. He previously served as senior legal counsel for Rhone-Poulenc in Paris in a variety of joint venture, merger and acquisition and licensing matters, including the creation of Aventis through a merger of Rhone-Poulenc and Hoechst.
Hans Fliri, is the newly appointed general manager of Scynexis Europe Limited. Fliri will manage the company’s European operations located near Cambridge, England. Most recently, he was VP of drug discovery at Cetek Corporation.
Previously, Fliri was the senior director of anti-infective discovery and lead generation at Rhone-Poulenc Rorer and later Aventis in Paris. He also held scientific management and technical roles at Novartis in Basel, Switzerland, and Vienna, Austria.
“The appointment of these uniquely talented and experienced individuals strengthens our ability to expand our research partnerships with the world’s top pharmaceutical companies and cutting-edge biotechnology companies,” said Yves Ribeill, president and chief executive officer of Scynexis.